Excellergy
Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases.
Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases.
Excellergy has raised $70.0M across 1 round. Its most recent round was a Series A of $70.0M in Oct 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Excellergy is featured in
Similar companies
Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading platform.
Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures safely.
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.
Curadel Surgical Innovations oversees the complete process of Curadel's FLARE contrast agents for image-guided surgery.
Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific tumor antigens.
Ventuno Biotech is a biotech company that is developing innovative cancer therapies.
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies
Treating the seeds of cancer
Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.